Navigation Links
Vanda Pharmaceuticals Reports Second Quarter 2011 Results
Date:8/4/2011

dicines Agency (EMA) notified Vanda that it had accepted for evaluation the Marketing Authorization Application (MAA) for oral iloperidone tablets.  It is estimated that schizophrenia affects approximately 5 million Europeans or 1.0% of the European Union (EU) population.  

On July 11, 2011, Vanda announced it had entered into an exclusive license agreement with Probiomed for the commercialization of Fanapt® in Mexico.  Under the terms of the agreement, Probiomed will seek regulatory approval for Fanapt® in Mexico.  With $9.3 billion in annual sales, Mexico is the second largest pharmaceutical market in Latin America and the 14th largest pharmaceutical market in the world.

On August 1, 2011, Vanda announced it had entered into an exclusive license agreement with Biotoscana for the commercialization of Fanapt® in Argentina.   On July, 28, 2011, Biotoscana filed for market approval of Fanapt® with the Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica (ANMAT).  With over $5 billion in annual sales, Argentina is the fourth largest pharmaceutical market in Latin America.

Enrollment continues in the first pivotal efficacy study of tasimelteon for the treatment of N24HSWD in blind individuals with no light perception.  An investigator meeting was held in May 2011 for the new German investigative sites.

Preparation for a tasimelteon Phase IIb/III study in major depression is ongoing and it is our expectation that the study will begin enrollment in the second half of 2011.CONFERENCE CALLVanda has scheduled a conference call for today, Thursday, August 4, 2011, at 10:00 AM ET.  During the call, Mihael H. Polymeropoulos, M.D., President and CEO, and James P. Kelly, Senior Vice President and CFO, will discuss the second quarter 2011 results and other corporate activities.  Investors can call 1-866-314-5232 (domestic) and 1-617-213-8052 (international) prio
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
2. Vanda Pharmaceuticals Reports Third Quarter 2007 Results
3. Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application
4. Vanda Presents Phase III Iloperidone Efficacy Data
5. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
6. Vanda Pharmaceuticals Provides Update on Iloperidone
7. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
8. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
9. Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
10. Vanda Pharmaceuticals Announces Expiration of Hart-Scott -Rodino Waiting Period for Exclusive License of Fanapt(TM)
11. Vanda Pharmaceuticals Announces U.S. Patent Allowance for a Long-Acting Injectable Formulation of Fanapt(TM) (iloperidone) in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015  OncoGenex Pharmaceuticals, Inc. ... report its second quarter 2015 financial results on Thursday, ... call and live webcast at 4:30 p.m. Eastern Time ... programs and a general corporate update. ... Relations page of the OncoGenex website at www.oncogenex.com ...
(Date:7/30/2015)... PLAINFIELD, N.J., July 30, 2015 PTC Therapeutics, ... update and reported financial results for the second quarter ... progressing on many fronts across the organization.  We are ... Duchenne muscular dystrophy clinical trial ever conducted with topline ... Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. "Translarna ...
(Date:7/30/2015)... -- Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ) ... patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics ... notice it received on May 21, 2015 from the ... was below certain of the Exchange,s continued listing standards, ... the NYSE MKT Company Guide, due to the delay ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2
... MASI ) today announced that its management is scheduled ... The Pierre Hotel in New York on Tuesday, November 15, ... the presentation will be available on the Masimo website at ... available following the live presentation. About ...
... Nov. 8, 2011 ChemoCentryx, Inc., today announced that ... the Annual Meeting of the American College of Rheumatology ... targets and inhibits the chemokine receptor known as CCR1, ... rheumatoid arthritis (RA).  Results showed that CCX354 was safe ...
Cached Medicine Technology:Masimo to Present at Lazard Capital Markets Healthcare Conference 2ChemoCentryx Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis 2ChemoCentryx Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis 3ChemoCentryx Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis 4
(Date:7/31/2015)... ... July 31, 2015 , ... The 2nd annual Ride to Fight On will ... October 3, 2015. The Ride to Fight On is a cycling fundraiser that benefits ... The West Clinic and The University of Tennessee Health Science Center. A health and ...
(Date:7/31/2015)... ... 31, 2015 , ... Coco Libre announced today that their flagship Organic Coconut ... 2015 Vans US Open of Surfing, July 25 through August 2 in Huntington Beach, ... on the market, is a natural choice given the Open’s commitment to sustainable practices. ...
(Date:7/31/2015)... ... July 31, 2015 , ... Well-known for its unique pastries ... wedding cakes with custom designs, making life just a little bit sweeter for ... cakes for each customer who orders one. , The bakery provides a full line ...
(Date:7/31/2015)... ... 2015 , ... Transfinder, a software company based in Schenectady, N.Y., achieved record ... year-over-year for the first six months ended June 30, 2015 compared with the same ... last year’s record-revenue mark of $10.4 million. , “We know what our customers need ...
(Date:7/31/2015)... NY (PRWEB) , ... July 31, 2015 , ... The ... marijuana, on research projects that evaluate the potential of related, experimental treatments. The collaboration ... Department of Health to award Columbia Care one of five state licenses to produce ...
Breaking Medicine News(10 mins):Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2Health News:Pastry Palace of Las Vegas Announces It Is Now Offering Custom Wedding Cakes in Las Vegas 2Health News:Transfinder Closes First Half of 2015 with Record Revenue 2Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 2Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 3
... students to benefit from program targeting kids in five-county ... American dream -- that children have more opportunities and ... at risk as the incidence of obesity among children ... could become the first in this country,s history to ...
... Andre Konski, M.D., M.B.A., has been offered ... Department of Radiation Oncology for the Wayne ... Chief for Radiation Oncology at the Barbara Ann ... Konski comes to Wayne State and ...
... Pierre,s Ice Cream Company, makers of,Hola Fruta!(R) ... innovation,called Yovation(TM). , (Photo: ... Yovation(TM) is a new premium, probiotic frozen ... and popularity of probiotic products and the,recognition by ...
... Plans Thousands of Franchisees Nationally With More than 1,800 ... eMed-ID, the world,s first medical identification franchise, announced today ... provides a personal USB device to consumers containing their ... for consumers to document their private medical history on ...
... Jan. 9 (HealthDay News) -- Parents may not always ... exercise habits, a new study shows. , Researchers reported ... Education and Behavior that mothers of preschool-aged children ... with older children did not. But when the children ...
... enhanced website designed to provide improved accessibility and ... Labs, a Zeus company, announces the launch of ... via the original URL and can be found ... with expanded content, including more information about Polymathic,s ...
Cached Medicine News:Health News:The Archdiocese of Philadelphia and Independence Blue Cross Team Up to Address Childhood Obesity 2Health News:The Archdiocese of Philadelphia and Independence Blue Cross Team Up to Address Childhood Obesity 3Health News:The Archdiocese of Philadelphia and Independence Blue Cross Team Up to Address Childhood Obesity 4Health News:Andre Konski, M.D., M.B.A., Accepts Radiation Oncology Position at Wayne State University and the Karmanos Cancer Institute 2Health News:Andre Konski, M.D., M.B.A., Accepts Radiation Oncology Position at Wayne State University and the Karmanos Cancer Institute 3Health News:Standing Ovation for Pierre's New Innovation! 2Health News:Standing Ovation for Pierre's New Innovation! 3Health News:World's First Medical Identification Franchise Launches at Miami's Franchise Expo South 2Health News:World's First Medical Identification Franchise Launches at Miami's Franchise Expo South 3Health News:Parents Not Best Barometer of Kid's Eating, Exercise Habits 2Health News:Polymathic Analytical Labs Launches New Website 2
Multipiece PMMA IOL - Sulcus Fixation....
Hydrophilic Acrylic Intraocular Lens (Refractive and Bifocal). Anterior Chamber Lens....
Raysoft Foldable Intraocular Lens....
HAPTIBAG Hydrophilic Acrylic Lens....
Medicine Products: